

ASX Release

SANOFI AVENTIS GROUPE AND SUDA Have Entered Into A Feasibility Agreement

PERTH, AUSTRALIA – 9 December 2019: SUDA Pharmaceuticals Ltd (ASX: SUD), a leader in oro-mucosal drug delivery, is pleased to announce that it has entered into a feasibility agreement with SANOFI-AVENTIS GROUPE (SANOFI) to investigate the feasibility of SUDA's OroMist Technology and SANOFI selected active ingredient.

The agreement is for SUDA to carry out a fully-funded feasibility study that will terminate on March 30th, 2021. As a feasibility study, this study is not intended to generate significant revenue.

Based on the outcomes of this feasibility study, SANOFI and SUDA may enter into further collaboration.

Further information:

Paul Hopper

Executive Chairman

SUDA Pharmaceuticals Ltd

Tel: +61 (0) 406 671 515

phopper@sudapharma.com

NOTES TO EDITORS:

About SUDA Pharmaceuticals Ltd

SUDA Pharmaceuticals Ltd (ASX: SUD) is a drug delivery company focused on oro-mucosal administration, headquartered in Perth, Western Australia. The Company is developing low-risk oral sprays using its OroMist® technology to reformulate existing pharmaceuticals. The many potential benefits of administering drugs through the oral mucosa (i.e.: cheeks, tongue, gums and palate) include ease of use, lower dosage, reduced side effects and faster response time. SUDA's product pipeline includes ZolpiMist™, a first-in-class oral spray of zolpidem for insomnia. ZolpiMist is marketed in the USA and SUDA has rights to the product outside of the US and Canada. Other products in development include oral sprays for the treatment of: migraine headache, chemotherapy-induced nausea and vomiting, erectile dysfunction, PAH, epileptic seizures and pre-procedural anxiety and cancer.

For more information, visit www.sudapharma.com

About Sanofi Aventis Groupe

Sanofi is dedicated to supporting people through their health challenges. Sanofi is a global biopharmaceutical company focused on human health. Sanofi prevents illness with vaccines, provide innovative treatments to fight pain and ease suffering. Sanofi stands by the few who suffer from rare diseases and the millions with long-term chronic conditions.

With more than 100,000 people in 100 countries, Sanofi is transforming scientific innovation into healthcare solutions around the globe.

Sanofi, Empowering Life

For more information: www.sanofi.com